Low-molecular-weight heparin versus unfractionated heparin in acute pulmonary thromboembolism Source: Eur Respir J 2001; 18: Suppl. 33, 381s Year: 2001
Enoxaparin versus unfractionated heparin in acute pulmonary thromboembolism Source: Eur Respir J 2002; 20: Suppl. 38, 237s Year: 2002
Randomized trial of low-molecular-weight heparin compared with unfractionated heparin for acute pulmonary embolism Source: Eur Respir J 2001; 18: Suppl. 33, 382s Year: 2001
Comparison between the administration of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) in the treatment of pulmonary embolism Source: Annual Congress 2007 - Venous thromboembolic disease Year: 2007
Effectiveness of anticoagulation with unfractionated heparin for acute pulmonary embolism Source: Virtual Congress 2021 – Insights into pulmonary embolism Year: 2021
One hour alteplase infusion plus low molecular weight heparin versus heparin alone in pulmonary embolism Source: Annual Congress 2003 - Pulmonary hypertension Year: 2003
Anti-Factor Xa levels correlate with recurrent venous thromboembolism and clinically relevant bleeding in patients receiving low-molecular-weight heparin. Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism Year: 2019
Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in gastrointestinal and pancreatobiliary cancer Source: International Congress 2018 – Diagnosis, prognostication and treatment of pulmonary embolism Year: 2018
Fixed or weight-adjusted dosis of enoxaparin as prophylaxis for venous thromboembolism in acutelly ill medical patients Source: Eur Respir J 2004; 24: Suppl. 48, 273s Year: 2004
Direct oral anticoagulants and low-molecular weight heparin for primary prevention of venous thromboembolism in cancer patients: a meta-analysis Source: Virtual Congress 2020 – From diagnosis to management of pulmonary embolism Year: 2020
Successful heparin desensitization after anaphylactic shock due to low molecular weight heparin Source: Eur Respir J 2005; 26: Suppl. 49, 134s Year: 2005
Comparison of two regimens of oral anticoagulation in pulmonary embolism Source: Eur Respir J 2006; 28: Suppl. 50, 632s Year: 2006
A clinical comparison of intrapleural heparin versus urokinase in the management of tuberculous pleurisy Source: Eur Respir J 2005; 26: Suppl. 49, 647s Year: 2005
The treatment of sub massive pulmonary embolism: Thrombolytic or heparin? Source: Annual Congress 2012 - Pulmonary circulation: acute and chronic pulmonary embolism Year: 2012
Treatment of VTE during pregnancy with a once-daily regimen of LMWH Source: Annual Congress 2007 - Acute and chronic pulmonary embolism Year: 2007
Efficacy and safety of systemic and prolonged low-dose thrombolysis in thromboembolic disease Source: Eur Respir J 2002; 20: Suppl. 38, 478s Year: 2002
Intrapleural heparin or heparin combined with human recombinant DNAase is not effective in the treatment of empyema in a rabbit model Source: Eur Respir J 2006; 28: Suppl. 50, 348s Year: 2006
Comparison of long –term outcomes of 50 mg rt-PA and 100 mg rt-PA in the management of acute pulmonary embolism Source: International Congress 2016 – Acute pulmonary embolism Year: 2016
Effectiveness of thrombolytic therapy in pulmonary thromboembolism Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007
Efficacy of thrombolytic agents in the treatment of pulmonary embolism Source: Eur Respir J 2005; 26: 864-874 Year: 2005